Streetbeat News

Stock Prices

QCOM

Qualcomm (NASDAQ:QCOM) is set to release its latest quarterly earnings report on November 1, 2023. Analysts estimate an earnings per share (EPS) of $1.80. The company's past performance shows it beat EPS estimates last quarter by $0.06, but this was followed by an 8.18% drop in share price. Qualcomm's shares were trading at $107.83 as of October 30, with a 52-week return of -4.72%.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:00 pm

URI

United Rentals (NYSE:URI) has outperformed the market over the past 10 years by 10.76% on an annualized basis, producing an average annual return of 19.69%. If an investor had bought $100 of URI stock 10 years ago, it would be worth $604.62 today.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:00 pm

LIN

Linde (NYSE:LIN) has outperformed the market over the past 15 years, producing an average annual return of 12.67%. If an investor had bought $100 of LIN stock 15 years ago, it would be worth $556.45 today. The company currently has a market capitalization of $183.71 billion.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 2:00 pm

SPY

The USA CB Consumer Confidence for October was reported at 102.6, slightly above the estimated 100, but lower than the previous month's 104.3.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 2:00 pm

GRTX

Galera Therapeutics Inc (GRTX) stock is sinking after the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced severe oral mucositis. The company also decided to halt the Phase 2b GRECO-2 trial of rucosopasem manganese in patients with locally advanced pancreatic cancer and the Phase 1/2 GRECO-1 trial of rucosopasem in patients with non-small-cell-lung-cancer, following futility analysis of the GRECO-2 trial. The company's shares are down 51.90% at $0.10.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 1:58 pm

SIEN

Trading of Sientra's shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:57 pm

CHK

Chesapeake Energy Corporation (NYSE:CHK) is set to release its Q3 financial results on Oct. 31, 2023. Analysts predict a quarterly earnings of 64 cents per share, down from $5.06 per share in the previous year. The company's revenue is expected to be $1.2 billion, compared to $2.01 billion in the year-ago period. Analysts from Benchmark, Wells Fargo, JP Morgan, Stephens & Co., and UBS have recently revised their ratings and price targets for the company.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:55 pm

ABBV

AMGN

Amgen Inc reported Q3 FY23 sales of $6.90 billion, slightly missing the consensus of $6.94 billion. Total revenues increased 4% Y/Y, driven by a 5% increase in product sales. Adjusted EPS increased 6% to $4.96, beating the consensus of $4.66. However, the company's stock fell by 3.78%. Amgen also raised its FY23 adjusted EPS and revenue guidance. Sales of Amjevita, Amgen's new biosimilar version of AbbVie Inc's arthritis drug Humira, rose 30% to $152 million.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 1:55 pm

SIEN

Shares of Sientra (SIEN) have been halted on a circuit breaker due to a significant drop in the stock price. The stock is currently down by 51.4%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 1:52 pm

AVTX

CDIO

GRTX

KTRA

PFE

SPRC

SRPT

US stocks traded lower following the release of economic reports. Pfizer Inc reported a Q3 loss with a 42% slump in sales. SciSparc Ltd, Cardio Diagnostics Holdings, and Avalo Therapeutics saw their shares rise after positive news, while Kintara Therapeutics, Galera Therapeutics, and Sarepta Therapeutics saw their shares drop due to negative developments.

Portfolio Pulse from Lisa Levin

October 31, 2023 | 1:52 pm